Global Testicular Cancer Drugs Market 2014-2018
DUBLIN, Apr. 25, 2014 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/dj4r99/global_testicular) has announced the addition of the "Global Testicular Cancer Drugs Market 2014-2018" report to their offering.
The current trend witnessed by the Global Testicular Cancer Drugs market is combination therapy being used for treating testicular cancer. Several oncologists believe that chemotherapy drugs are most effective when given in combination with radiation therapy and surgery. Cancer cells that are confined locally can be easily treated by surgery or radiation therapy, while cancer cells that have spread to distant sites can be killed by chemotherapy.
Therefore, combination therapy helps in completely removing the tumor or destroying the cancerous cells in the patient's body. The combination therapy is decided depending on the size of the tumor and the risk of recurrence. Moreover, for treatment of testicular cancer, a combination of two or more drugs is usually given. Some of the combinations are BEP, EP (etoposide and cisplatin), and VIP (vinblastine plus ifosfamide and cisplatin).
According to the report, one of the key drivers is the increasing prevalence of testicular cancer due to a variety of factors such as congenital abnormalities, family history, abnormal testicular development, and HIV infection. This has increased the demand for testicular cancer drugs as these drugs have greatly improved survival rate for patients with both seminomas and non-seminomas type of testicular cancer.
Further, the report states that one of the main challenges in the market is the presence of alternative testicular cancer treatments that do not use drugs, thereby limiting the consumption of drugs.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Key Topics Covered:
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
04. Market Research Methodology
06. Market Landscape
07. Testicular Cancer by Type
08. Testicular Cancer Disease by Stages
09. Treatment Options
10. Clinical Trial Snapshot
11. Geographical Segmentation
12. Buying Criteria
13. Rate of Incidence and Prevalence
14. Market Growth Drivers
15. Drivers and their Impact
16. Market Challenges
17. Impact of Drivers and Challenges
18. Market Trends
19. Trends and their Impact
20. Vendor Landscape
21. Key Vendor Analysis
22. Other Reports in this Series
- Bristol-Myers Squibb Co.
- Hospira Inc.
- Teva Pharmaceutical Industries Ltd.
- ZIOPHARM Oncology Inc.
For more information visit http://www.researchandmarkets.com/research/dj4r99/global_testicular
Media Contact: Laura Wood, +353-1-481-1716, firstname.lastname@example.org
SOURCE Research and Markets